AlloGen-LI
PreclinicalSmall molecule
AlloGen-LI is one of 6 small molecule programs targeting Spinal Stenosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Spinal Stenosis
#DrugCompanyPhaseTrials
1Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Marcaine
IInnocoll
Approved
Celebrex
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Cytotec
PfizerPreclinical
Depomedrol
IIsfahan University of Medical Sciences
Preclinical
AlloGen-LI
UUniversity of Southern California
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AlloGen-LI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details